Free Newsletter
Computing method offers shortcut to right flu vax
Investigators at Rice University say that they have devised a computational method that offers a faster and cheaper way to determine the formula for each new flu vaccine. And they say that the new approach could work with bird flu vaccines as well.
Currently researchers use animal models or genetic assays to test proposed flu vaccines. In the new method developed at Rice, flu virus mutations are assigned numerical scores. Michael Deem, Rice's John W. Cox professor of bioengineering, physics and astronomy, and colleagues developed the method so they could assign a number that captured the amount of difference or similarity between flu strains. The method can also be used to test how effective a vaccine will be against divergent strains. To verify this, the team checked their results against flu vaccine data collected by the World Health Organization from 1971 to 2004.
"For seasonal influenza, we validated our model against observational data compiled by the World Health Organization's Global Influenza Surveillance Network," Deem said. "We also ran tests against bird flu data. We found that multiple-component bird flu vaccines appeared to be helpful in controlling the simultaneous multiple introduction of bird flu strains."
Each year, world health authorities create a flu vaccine that protects against three types of seasonal flu--two subtypes of type A flu and one subtype of type B.
- check out the press release
Related Articles:
1918 flu survivors' blood may hold key to better vax
GSK bird flu vaccine wins race for European OK
Universal flu vaccine shows early promise
Breakthrough reported in flu vaccine research
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D;: Evolving strategies to rejuvenate R&D; efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges




Click here to get the FierceVaccines email newsletter for FREE!
Be the first to comment